Amelioration of experimental colitis by a novel nanoselenium-silymarin mixture

Toxicology Mechanisms and Methods

Volumn 21, Issue 3, 2011, Pages 200-208

  Miroliaee, Amir Ebrahim ^a   Esmaily, Hadi ^b   Vaziri Bami, Amanollah ^a   Baeeri, Maryam ^a   Shahverdi, Ahmad Reza ^a   Abdollahi, Mohammad ^a  

^a TEHRAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^b SHAHID BEHESHTI UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

colitis; cytokines; inflammatory bowel disease; nano Se; NF B; oxidative stress; Silymarin; TNBS

Indexed keywords

ANTIOXIDANT; BIOLOGICAL MARKER; DEXAMETHASONE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INTERLEUKIN 1BETA; MYELOPEROXIDASE; NANOPARTICLE; NANOSELENIUM; SELENIUM; SILYMARIN; TRINITROBENZENESULFONIC ACID; TUMOR NECROSIS FACTOR ALPHA; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ANTIOXIDANT ACTIVITY; ARTICLE; CLINICAL EVALUATION; COLITIS; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; ENZYME ACTIVITY; LIPID PEROXIDATION; MALE; MICROSCOPY; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN CARBONYLATION; RAT;

ANIMALS; ANTIOXIDANTS; BIOLOGICAL MARKERS; COLITIS; COLON; DISEASE MODELS, ANIMAL; INTERLEUKIN-1BETA; LIPID PEROXIDATION; MALE; NANOPARTICLES; NF-KAPPA B; OXIDATIVE STRESS; PEROXIDASE; PROTEIN CARBONYLATION; RATS; RATS, WISTAR; SELENIUM; SILYMARIN; TUMOR NECROSIS FACTOR-ALPHA;

ANIMALIA; RATTUS;

EID: 79951933028     PISSN: 15376516     EISSN: 15376524     Source Type: Journal    
DOI: 10.3109/15376516.2010.547887     Document Type: Article

References (39)

1. Abdolghaffari AH, Baghaei A, Moayer F, Esmaily H, Baeeri M, Monsef-Esfahani HR, Hajiaghaee R, Abdollahi M. 2010. On the benefit of Teucrium in murine colitis through improvement of toxic inflammatory mediators. Hum Exp Toxicol 29:287-295.
2. Abdollahi M, Rahmat-Jirdeh N, Soltaninejad K. 2001. Protection by selenium of lead-acetate-induced alterations on rat submandibular gland function. Hum Exp Toxicol 20:28-33.
3. Amini-Shirazi N, Hoseini A, Ranjbar A, Mohammadirad A, Khoshakhlagh P, Yasa N, Abdollahi M. 2009. Inhibition of tumor necrosis factor and nitrosative/ oxidative stresses by Ziziphora clinopoides (Kahlioti); a molecular mechanism of protection against dextran sodium sulfate-induced colitis in mice. Toxicol Mech Methods 19:183-189.
4. Arteel GE, Briviba K, Sies H. 1999. Protection against peroxynitrite. FEBS Lett 445:226-230.
5. Astaneie F, Afshari M, Mojtahedi A, Mostafalou S, Zamani MJ, Larijani B, Abdollahi M. 2005. Total antioxidant capacity and levels of epidermal growth factor and nitric oxide in blood and saliva of insulin-dependent diabetic patients. Arch Med Res 36:376-381.
6. Blumberg RS, Saubermann LJ, Strober W. 1999. Animal models of mucosal inflammation and their relation to human inflammatory bowel disease. Curr Opin Immunol 11:648-656.
7. Bouma G, Strober W. 2003. The immunological and genetic basis of inflammatory bowel disease. Nat Rev Immunol 3:521-533.
8. Bradford MM. 1976. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding. Anal Biochem 72:248-254.
9. Duntas LH. 2009. Selenium and inflammation: underlying anti-inflammatory mechanisms. Horm Metab Res 41:443-447.
10. Esmaily H, Hosseini-Tabatabaei A, Rahimian R, Khorasani R, Baeeri M, Barazesh-Morgani A, Yasa N, Khademi Y, Abdollahi M. 2009. On the benefits of silymarin in murine colitis by improving balance of destructive cytokines and reduction of toxic stress in the bowel cells. Cent Eur J Biol 4:204-213.
11. Fesharaki PJ, Nazari P, Shakibaie M, Rezaie S, Banoee M, Abdollahi M, Shahverdi AR. 2010. Biosynthesis of selenium nanoparticles using Klebsiella pneumonia and their recovery by a simple sterilization process. Braz J Microbiol. 41:461-466.
12. Gazák R, Walterová D, Kren V. 2007. Silybin and silymarin-new and emerging applications in medicine. Curr Med Chem 14:315-338.
13. Ghazanfari G, Minaie B, Yasa N, Nakhai LA, Mohammadirad A, Nikfar S, Dehghan G, Boushehri VS, Jamshidi H, Khorasani R, Salehnia A, Abdollahi M. 2006. Biochemical and histopathological evidences for beneficial effects of satureja khuzestanica jamzad essential oil on the mouse model of inflammatory bowel diseases. Toxicol Mech Methods 16:365-372.
14. Hanauer SB. 2006. Inflammatory bowel disease: epidemiology, pathogenesis, and therapeutic opportunities. Inflamm Bowel Dis 12 (Suppl 1):S3-S9.
15. Hosseini-Tabatabaei A, Abdollahi M. 2008. Potassium channel openers and improvement of toxic stress: do they have role in the management of inflammatory bowel disease? Inflamm Allergy Drug Targets 7:129-135.
16. Inoue J, Gohda J, Akiyama T, Semba K. 2007. NF-kappaB activation in development and progression of cancer. Cancer Sci 98:268-274.
17. Jurjus AR, Khoury NN, Reimund JM. 2004. Animal models of inflammatory bowel disease. J Pharmacol Toxicol Methods 50:81-92.
18. Katiyar SK, Roy AM, Baliga MS. 2005. Silymarin induces apoptosis primarily through a p53-dependent pathway involving Bcl-2/Bax, cytochrome c release, and caspase activation. Mol Cancer Ther 4:207-216.
19. Khoshakhlagh P, Bahrololoumi-Shapourabadi M, Mohammadirad A, Ashtaral-Nakhai L, Minaie B, Abdollahi M. 2007. Beneficial effect of phosphodiesterase- 5 inhibitor in experimental inflammatory bowel disease; molecular evidence for involvement of oxidative stress. Toxicol Mech Methods 17:281-288.
20. Kreydiyyeh SI, Al-Sadi R. 2002. The mechanism by which interleukin-1 beta reduces net fluid absorption from the rat colon. Eur Cytokine Netw 13:358-363.
21. Malihi F, Hosseini-Tabatabaei A, Esmaily H, Khorasani R, Baeeri M, Abdollahi M. 2009. Improvement of inflammatory and toxic stress biomarkers by silymarin in a murine model of type one diabetes mellitus. Cent Eur J Biol 4:369-380.
22. Manna SK, Mukhopadhyay A, Van NT, Aggarwal BB. 1999. Silymarin suppresses TNF-induced activation of NF-kappa B, c-Jun N-terminal kinase, and apoptosis. J Immunol 163:6800-6809.
23. Morris GP, Beck PL, Herridge MS, Depew WT, Szewczuk MR, Wallace JL. 1989. Hapten-induced model of chronic inflammation and ulceration in the rat colon. Gastroenterology 96:795-803.
24. Nakhai LA, Mohammadirad A, Yasa N, Minaie B, Nikfar S, Ghazanfari G, Zamani MJ, Dehghan G, Jamshidi H, Boushehri VS, Khorasani R, Abdollahi M. 2007. Benefits of Zataria multiflora Boiss in experimental model of mouse inflammatory bowel disease. Evid Based Complement Alternat Med 4:43-50.
25. Neurath MF, Becker C, Barbulescu K. 1998. Role of NF-kappaB in immune and inflammatory responses in the gut. Gut 43:856-860.
26. Pavlick KP, Laroux FS, Fuseler J, Wolf RE, Gray L, Hoffman J, Grisham MB. 2002. Role of reactive metabolites of oxygen and nitrogen in inflammatory bowel disease. Free Radic Biol Med 33:311-322.
27. Peng D, Zhang J, Liu Q, Taylor EW. 2007. Size effect of elemental selenium nanoparticles (nano-Se) at supranutritional levels on selenium accumulation and glutathione S-transferase activity. J Inorg Biochem 101:1457-1463.
28. Radfar M, Larijani B, Hadjibabaie M, Rajabipour B, Mojtahedi A, Abdollahi M. 2005. Effects of pentoxifylline on oxidative stress and levels of EGF and NO in blood of diabetic type-2 patients; a randomized, doubleblind placebo-controlled clinical trial. Biomed Pharmacother 59: 302-306.
29. Rahimi R, Nikfar S, Abdollahi M. 2007. Do anti-tumor necrosis factors induce response and remission in patients with acute refractory Crohn's disease? A systematic meta-analysis of controlled clinical trials. Biomed Pharmacother 61:75-80.
30. Rayman MP. 2000. The importance of selenium to human health. Lancet 356:233-241.
31. Rezaie A, Ghorbani F, Eshghtork A, Zamani MJ, Dehghan G, Taghavi B, Nikfar S, Mohammadirad A, Daryani NE, Abdollahi M. 2006. Alterations in salivary antioxidants, nitric oxide, and transforming growth factor-beta 1 in relation to disease activity in Crohn's disease patients. Ann N Y Acad Sci 1091:110-122.
32. Rezaie A, Parker RD, Abdollahi M. 2007. Oxidative stress and pathogenesis of inflammatory bowel disease: an epiphenomenon or the cause? Dig Dis Sci 52:2015-2021.
33. Sanchez-Munoz F, Dominguez-Lopez A, Yamamoto-Furusho JK. 2008. Role of cytokines in inflammatory bowel disease. World J Gastroenterol 14:4280-4288.
34. Sandborn WJ, Hanauer SB. 1999. Antitumor necrosis factor therapy for inflammatory bowel disease: a review of agents, pharmacology, clinical results, and safety. Inflamm Bowel Dis 5:119-133.
35. Soleimani H, Ranjbar A, Baeeri M, Mohammadirad A, Khorasani R, Yasa N, Abdollahi M. 2008. Rat plasma oxidation status after Nigella sativa L. botanical treatment in CCL(4)-treated rats. Toxicol Mech Methods 18:725-731.
36. Tirosh O, Levy E, Reifen R. 2007. High selenium diet protects against TNBSinduced acute inflammation, mitochondrial dysfunction, and secondary necrosis in rat colon. Nutrition 23:878-886.
37. Vunta H, Davis F, Palempalli UD, Bhat D, Arner RJ, Thompson JT, Peterson DG, Reddy CC, Prabhu KS. 2007. The anti-inflammatory effects of selenium are mediated through 15-deoxy-delta12,14-prostaglandin J2 in macrophages. J Biol Chem 282:17964-17973.
38. Wang H, Zhang J, Yu H. 2007. Elemental selenium at nano size possesses lower toxicity without compromising the fundamental effect on selenoenzymes: comparison with selenomethionine in mice. Free Radic Biol Med 42:1524-1533.
39. Zamamiri-Davis F, Lu Y, Thompson JT, Prabhu KS, Reddy PV, Sordillo LM, Reddy CC. 2002. Nuclear factor-kappaB mediates over-expression of cyclooxygenase-2 during activation of RAW 264.7 macrophages in selenium deficiency. Free Radic Biol Med 32: 890-897.